The disclosure provides a device for sustained release of a therapeutic agent, comprising a capsule configured for implantation and having a reservoir; a nanoporous membrane with a plurality of pores; the therapeutic agent disposed within the reservoir; wherein the nanoporous membrane provides a diffusion path for the therapeutic agent out of the reservoir; and the device further comprising an anti-inflammatory agent.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
2.
STABILIZATION OF PEPTIDES AND PROTEINS IN IMPLANTABLE DEVICES AND FORMULATIONS
The disclosure pertains to the field of treatment of patients with implantable delivery devices for long-term release of therapeutic agents. In particular, the disclosure pertains to devices, formulations and methods to stabilize peptide and protein formulations.
The disclosure pertains to the field of treatment of patients with implantable delivery devices for long-term release of therapeutic agents. In particular, the disclosure pertains to devices, formulations, and methods to manage body weight.
The present disclosure provides formulations, methods and implantable devices that improve patient compliance by releasing a desired therapeutic agent such as semaglutide for a long time period, such as 1 year or more. The semaglutide concentration (w/w) is more than 1%, such as about 1.1 % w/w to about 35% w/w.
The disclosure provides devices and methods for sustained release of a therapeutic agent, the device comprising: a capsule configured for implantation and having a reservoir; a nanoporous membrane with a plurality of pores attached to the capsule and providing a diffusion path for release of the therapeutic agent out of the reservoir; a formulation of the therapeutic agent contained within the reservoir; the formulation including a surfactant; and wherein the surfactant increases the rate of release of the therapeutic agent through the membrane into an environment of use.
The disclosure provides a device for sustained release of a therapeutic agent, comprising a capsule configured for implantation and having a reservoir; a nanoporous membrane with a plurality of pores; the therapeutic agent disposed within the reservoir; wherein the nanoporous membrane provides a diffusion path for the therapeutic agent out of the reservoir; and the device further comprising an anti-inflammatory agent.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The disclosure provides methods for reducing a thermal start-up burst release from an implantable device for controlled release of a therapeutic agent from a device comprising a capsule configured for implantation and having a reservoir. The disclosure further provides methods to reduce peak plasma concentration of a therapeutic agent from an implantable device for controlled release of the therapeutic agent.
The disclosure pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the disclosure have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended-release configuration or a sustained release carrier.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present disclosure provides compositions of a therapeutic agent and a release rate controlling agent for controlling the rate of release of the therapeutic agent from a reservoir of an implantable drug delivery system. The present disclosure also includes an implantable drug delivery systems incorporating the compositions of the present disclosure as well as methods of treating diabetes using the compositions and implantable drug delivery systems.
The present disclosure provides compositions of a therapeutic agent and a release rate controlling agent for controlling the rate of release of the therapeutic agent from a reservoir of an implantable drug delivery system. The present disclosure also includes an implantable drug delivery systems incorporating the compositions of the present disclosure as well as methods of treating diabetes using the compositions and implantable drug delivery systems.
Embodiments of the invention include devices, compositions and methods for the controlled release of therapeutic substances, such as drugs. Control over the rate of release of the therapeutic substances from the devices is achieved by the use of nanoporous membranes in which the pore size is matched to the molecular diameter of the therapeutic substances. Some embodiments of the invention achieve zero-order release by the use of membranes with a pore diameter that is more than five times the Stokes' diameter of the therapeutic substance released.
The disclosure pertains to the field of treatment of patients with implantable delivery devices for long-term release of therapeutic agents. In particular, the disclosure provides devices and methods for the stabilization of the therapeutic agents inside the device for the duration of the implantation. The devices control the long-term release of the therapeutic agents by using a nanoporous membrane. The stabilization is achieved by using high-molecular weight stabilizers of a size that is larger than the diameter of the pores of the membrane, thereby preventing the release of the stabilizers.
The disclosure pertains to the field of treatment of patients with implantable delivery devices for long-term release of therapeutic agents. In particular, the disclosure provides devices and methods for the stabilization of the therapeutic agents inside the device for the duration of the implantation. The devices control the long-term release of the therapeutic agents by using a nanoporous membrane. The stabilization is achieved by using high-molecular weight stabilizers of a size that is larger than the diameter of the pores of the membrane, thereby preventing the release of the stabilizers.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C08G 83/00 - Macromolecular compounds not provided for in groups
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended release configuration.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention.
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
The invention pertains to apparatuses, means and methods to promote uptake of biocompatible fluids into a reservoir of an implantable drug delivery system though a porous membrane. Embodiments of the invention promote fluid uptake by creating a pressure differential between the reservoir of the drug delivery device and the biocompatible fluid outside the device.
Embodiments of the invention include devices, compositions and methods for the controlled release of therapeutic substances, such as drugs. Control over the rate of release of the therapeutic substances from the devices is achieved by the use of nanoporous membranes in which the pore size is matched to the molecular diameter of the therapeutic substances. Some embodiments of the invention achieve zero-order release by the use of membranes with a pore diameter that is more than five times the Stokes' diameter of the therapeutic substance released.
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, and means to promote water uptake into the reservoir upon implantation. In some embodiments the means include a gas with a higher solubility in than air water.
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended release configuration.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/00 - Medicinal preparations characterised by special physical form
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The application pertains to apparatuses, means and methods to promote uptake of biocompatible fluids into a reservoir of an implantable drug delivery system (3006) though a porous membrane (3008). Examples of the application promote fluid uptake by creating a pressure differential between the reservoir of the drug delivery device and the biocompatible fluid outside the device.
Embodiments of the invention include devices, compositions and methods for the controlled release of therapeutic substances, such as drugs. Control over the rate of release of the therapeutic substances from the devices is achieved by the use of nanoporous membranes in which the pore size is matched to the molecular diameter of the therapeutic substances. Some embodiments of the invention achieve zero-order release by the use of membranes with a pore diameter that is more than five times the Stokes' diameter of the therapeutic substance released.
The present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention.
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
The invention pertains to apparatuses, means and methods to promote uptake of fluids into a reservoir of an implantable drug delivery system though a porous membrane. Embodiments of the invention promote fluid uptake by creating a pressure differential between the reservoir of the drug delivery device and the environment of the device after implantation, for instance a subcutaneous pocket.
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, and means to promote water uptake into the reservoir upon implantation. In some embodiments the means include a gas with a higher solubility in than air water.
The disclosure is generally related to medical devices, systems, and methods. In particular embodiments, implant applicators may be provided for subdermally inserting an implant. In some aspects, an applicator may include a housing defining a body of the applicator, and a cannula coupled with the housing and extending distally from the body of the applicator. In some embodiments, a cannula guide may extend from the body of the applicator and may help a user align the applicator at a desired angle relative to the skin surface prior to insertion of the cannula into the skin. The applicator may further include a skin guide that limits skin buckling against the applicator housing during cannula insertion into the skin. The cannula may have an implant holding section where an inner surface of the cannula is inwardly indented such that the inner surface of the cannula friction fits with an implant.
The present invention provides a method for controlling the internal diameter of nanopores to afford nanopore membranes with a zero-order rate of release of a therapeutic agent.
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, and means to promote water uptake into the reservoir upon implantation. In some embodiments the means include a gas with a higher solubility in than air water.
The invention pertains to apparatuses, means and methods to promote uptake of fluids into a reservoir of an implantable drug delivery system though a porous membrane. Embodiments of the invention promote fluid uptake by creating a pressure differential between the reservoir of the drug delivery device and the environment of the device after implantation, for instance a subcutaneous pocket.
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended release configuration.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, and means to promote water uptake into the reservoir upon implantation. In some embodiments the means include a gas with a higher solubility in than air water.
The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended release configuration.
The present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention.
The present invention provides a method for controlling the internal diameter of nanopores to afford nanopore membranes with a zero-order rate of release of a therapeutic agent.
The present invention provides a device including a titania nanotube membrane having a plurality of titania nanotubes on a titanium substrate where the titania nanotubes are open at both ends and capable of allowing diffusion of liquids or solids from one side of the membrane to the other through the titania nanotubes. Methods of making the titania nanotube membrane are also provided.
The present invention provides a device including a titania nanotube membrane having a plurality of titania nanotubes on a titanium substrate where the titania nanotubes are open at both ends and capable of allowing diffusion of liquids or solids from one side of the membrane to the other through the titania nanotubes. Methods of making the titania nanotube membrane are also provided.
C09D 5/44 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes for electrophoretic applications
36.
POLYMERIC STABILIZING AGENTS FOR IMPLANTABLE DRUG DELIVERY DEVICES
The disclosure pertains to the field of treatment of patients with implantable delivery devices for long-term release of therapeutic agents. In particular, the disclosure provides devices and methods for the stabilization of the therapeutic agents inside the device for the duration of the implantation. The devices control the long-term release of the therapeutic agents by using a nanoporous membrane. The stabilization is achieved by using high-molecular weight stabilizers of a size that is larger than the diameter of the pores of the membrane, thereby preventing the release of the stabilizers.
The present disclosure provides compositions of a therapeutic agent and a release rate controlling agent for controlling the rate of release of the therapeutic agent from a reservoir of an implantable drug delivery system. The present disclosure also includes an implantable drug delivery systems incorporating the compositions of the present disclosure as well as methods of treating diabetes using the compositions and implantable drug delivery systems.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
patents
